Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.

<h4>Background</h4>Adherence to oral anticoagulant therapy in patients with atrial fibrillation (AF) in China is low. Patient preference, one of the main reasons for discontinuation of oral anticoagulant therapy, is an unfamiliar concept in China.<h4>Methods and findings</h4>...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jiaxi Zhao, Hao Wang, Xue Li, Yang Hu, Vincent K C Yan, Carlos K H Wong, Yutao Guo, Marco K H Cheung, Gregory Y H Lip, Chung-Wah Siu, Hung-Fat Tse, Esther W Chan
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Acceso en línea:https://doaj.org/article/4f2ea084ce1340b4b07485e4d70d7ef6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4f2ea084ce1340b4b07485e4d70d7ef6
record_format dspace
spelling oai:doaj.org-article:4f2ea084ce1340b4b07485e4d70d7ef62021-12-02T19:55:38ZImportance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.1549-12771549-167610.1371/journal.pmed.1003730https://doaj.org/article/4f2ea084ce1340b4b07485e4d70d7ef62021-08-01T00:00:00Zhttps://doi.org/10.1371/journal.pmed.1003730https://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Adherence to oral anticoagulant therapy in patients with atrial fibrillation (AF) in China is low. Patient preference, one of the main reasons for discontinuation of oral anticoagulant therapy, is an unfamiliar concept in China.<h4>Methods and findings</h4>A discrete choice experiment (DCE) was conducted to quantify patient preference on 7 attributes of oral anticoagulant therapy: antidote (yes/no), food-drug interaction (yes/no), frequency of blood monitoring (no need, every 6/3/1 month[s]), risk of nonfatal major bleeding (0.7/3.1/5.5/7.8[%]), risk of nonfatal stroke (ischemic/hemorrhagic) or systemic embolism (0.6/3.2/5.8/8.4[%]), risk of nonfatal acute myocardial infarction (AMI) (0.2/1.0/1.8/2.5[%]), and monthly out-of-pocket cost (0/120/240/360 RMB) (0 to 56 USD). A total of 16 scenarios were generated by using D-Efficient design and were randomly divided into 2 blocks. Eligible patients were recruited and interviewed from outpatient and inpatient settings of 2 public hospitals in Beijing and Shenzhen, respectively. Patients were presented with 8 scenarios and asked to select 1 of 3 options: 2 unlabeled hypothetical treatments and 1 opt-out option. Mixed logit regression model was used for estimating patients' preferences of attributes of oral anticoagulants and willingness to pay (WTP) with adjustments for age, sex, education level, income level, city, self-evaluated health score, histories of cardiovascular disease/other vascular disease/any stroke/any bleeding, and use of anticoagulant/antiplatelet therapy. A total of 506 patients were recruited between May 2018 and December 2019 (mean age 70.3 years, 42.1% women). Patients were mainly concerned about the risks of AMI (β: -1.03; 95% CI: -1.31, -0.75; p < 0.001), stroke or systemic embolism (β: -0.81; 95% CI: -0.90, -0.73; p < 0.001), and major bleeding (β: -0.69; 95% CI: -0.78, -0.60; p < 0.001) and were willing to pay more, from up to 798 RMB to 536 RMB (124 to 83 USD) monthly. The least concerning attribute was frequency of blood monitoring (β: -0.31; 95% CI: -0.39, -0.24; p < 0.001). Patients had more concerns about food-drug interactions even exceeding preferences on the 3 risks, if they had a history of stroke or bleeding (β: -2.47; 95% CI: -3.92, -1.02; p < 0.001), recruited from Beijing (β: -1.82; 95% CI: -2.56, -1.07; p < 0.001), or men (β: -0.96; 95% CI: -1.36, -0.56; p < 0.001). Patients with lower educational attainment or lower income weighted all attributes lower, and their WTP for incremental efficacy and safety was minimal. Since the patients were recruited from 2 major hospitals from developed cities in China, further studies with better representative samples would be needed.<h4>Conclusions</h4>Patients with AF in China were mainly concerned about the safety and effectiveness of oral anticoagulant therapy. The preference weighting on food-drug interaction varied widely. Patients with lower educational attainment or income levels and less experience of bleeding or stroke had more reservations about paying for oral anticoagulant therapies with superior efficacy, safety, and convenience of use.Jiaxi ZhaoHao WangXue LiYang HuVincent K C YanCarlos K H WongYutao GuoMarco K H CheungGregory Y H LipChung-Wah SiuHung-Fat TseEsther W ChanPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 18, Iss 8, p e1003730 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Jiaxi Zhao
Hao Wang
Xue Li
Yang Hu
Vincent K C Yan
Carlos K H Wong
Yutao Guo
Marco K H Cheung
Gregory Y H Lip
Chung-Wah Siu
Hung-Fat Tse
Esther W Chan
Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
description <h4>Background</h4>Adherence to oral anticoagulant therapy in patients with atrial fibrillation (AF) in China is low. Patient preference, one of the main reasons for discontinuation of oral anticoagulant therapy, is an unfamiliar concept in China.<h4>Methods and findings</h4>A discrete choice experiment (DCE) was conducted to quantify patient preference on 7 attributes of oral anticoagulant therapy: antidote (yes/no), food-drug interaction (yes/no), frequency of blood monitoring (no need, every 6/3/1 month[s]), risk of nonfatal major bleeding (0.7/3.1/5.5/7.8[%]), risk of nonfatal stroke (ischemic/hemorrhagic) or systemic embolism (0.6/3.2/5.8/8.4[%]), risk of nonfatal acute myocardial infarction (AMI) (0.2/1.0/1.8/2.5[%]), and monthly out-of-pocket cost (0/120/240/360 RMB) (0 to 56 USD). A total of 16 scenarios were generated by using D-Efficient design and were randomly divided into 2 blocks. Eligible patients were recruited and interviewed from outpatient and inpatient settings of 2 public hospitals in Beijing and Shenzhen, respectively. Patients were presented with 8 scenarios and asked to select 1 of 3 options: 2 unlabeled hypothetical treatments and 1 opt-out option. Mixed logit regression model was used for estimating patients' preferences of attributes of oral anticoagulants and willingness to pay (WTP) with adjustments for age, sex, education level, income level, city, self-evaluated health score, histories of cardiovascular disease/other vascular disease/any stroke/any bleeding, and use of anticoagulant/antiplatelet therapy. A total of 506 patients were recruited between May 2018 and December 2019 (mean age 70.3 years, 42.1% women). Patients were mainly concerned about the risks of AMI (β: -1.03; 95% CI: -1.31, -0.75; p < 0.001), stroke or systemic embolism (β: -0.81; 95% CI: -0.90, -0.73; p < 0.001), and major bleeding (β: -0.69; 95% CI: -0.78, -0.60; p < 0.001) and were willing to pay more, from up to 798 RMB to 536 RMB (124 to 83 USD) monthly. The least concerning attribute was frequency of blood monitoring (β: -0.31; 95% CI: -0.39, -0.24; p < 0.001). Patients had more concerns about food-drug interactions even exceeding preferences on the 3 risks, if they had a history of stroke or bleeding (β: -2.47; 95% CI: -3.92, -1.02; p < 0.001), recruited from Beijing (β: -1.82; 95% CI: -2.56, -1.07; p < 0.001), or men (β: -0.96; 95% CI: -1.36, -0.56; p < 0.001). Patients with lower educational attainment or lower income weighted all attributes lower, and their WTP for incremental efficacy and safety was minimal. Since the patients were recruited from 2 major hospitals from developed cities in China, further studies with better representative samples would be needed.<h4>Conclusions</h4>Patients with AF in China were mainly concerned about the safety and effectiveness of oral anticoagulant therapy. The preference weighting on food-drug interaction varied widely. Patients with lower educational attainment or income levels and less experience of bleeding or stroke had more reservations about paying for oral anticoagulant therapies with superior efficacy, safety, and convenience of use.
format article
author Jiaxi Zhao
Hao Wang
Xue Li
Yang Hu
Vincent K C Yan
Carlos K H Wong
Yutao Guo
Marco K H Cheung
Gregory Y H Lip
Chung-Wah Siu
Hung-Fat Tse
Esther W Chan
author_facet Jiaxi Zhao
Hao Wang
Xue Li
Yang Hu
Vincent K C Yan
Carlos K H Wong
Yutao Guo
Marco K H Cheung
Gregory Y H Lip
Chung-Wah Siu
Hung-Fat Tse
Esther W Chan
author_sort Jiaxi Zhao
title Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
title_short Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
title_full Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
title_fullStr Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
title_full_unstemmed Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: A discrete choice experiment.
title_sort importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in china: a discrete choice experiment.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/4f2ea084ce1340b4b07485e4d70d7ef6
work_keys_str_mv AT jiaxizhao importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT haowang importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT xueli importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT yanghu importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT vincentkcyan importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT carloskhwong importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT yutaoguo importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT marcokhcheung importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT gregoryyhlip importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT chungwahsiu importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT hungfattse importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
AT estherwchan importanceofattributesandwillingnesstopayfororalanticoagulanttherapyinpatientswithatrialfibrillationinchinaadiscretechoiceexperiment
_version_ 1718375837204480000